Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 3Phase NA 1Phase 2/3 1Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 12Leukemia 5Myelodysplastic Syndromes 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Hematologic Neoplasms 2Recurrence 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Hodgkin Disease 1Burkitt Lymphoma 1

Interventions

Azacitidine 56Cyclophosphamide 44fludarabine phosphate 42fludarabine 37Decitabine 27venetoclax 26Cytarabine 25Tacrolimus 20Specimen Handling 18Filgrastim 18Busulfan 18Melphalan 17Whole-Body Irradiation 16Mycophenolic Acid 16Antilymphocyte Serum 14Granulocyte Colony-Stimulating Factor 12Clofarabine 12Biopsy 12Peripheral Blood Stem Cell Transplantation 11Injections 11Etoposide 11Methotrexate 10thymoglobulin 9Thiotepa 9Stem Cell Transplantation 9Lenalidomide 9decitabine and cedazuridine drug combination 8aldesleukin 8Sirolimus 8Nivolumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Myelodysplastic Syndromes × CPX-351 × Clear all
NCT03393611 2022-12-21

CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome

Weill Medical College of Cornell University

Phase 1 Completed
14 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03555955 2021-07-22

A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351

Jazz Pharmaceuticals

Phase 1 Completed
21 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00875693 2018-01-17

A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)

Weill Medical College of Cornell University

Phase 1 Completed
47 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡